Antitumor Effects of Sunitinib or Sorafenib in Patients With Metastatic Renal Cell Carcinoma Who Received Prior Antiangiogenic Therapy
Author:
Affiliation:
1. Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, Ohio
2. Cleveland Clinic Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio
3. Glickman Urologic Institute, Cleveland Clinic, Cleveland, Ohio
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Urology
Reference19 articles.
1. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy;Dvorak;J Clin Oncol,2002
2. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma;Rini;J Clin Oncol,2005
3. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma;Motzer;J Clin Oncol,2006
4. Sunitinib in patients with metastatic renal cell carcinoma;Motzer;JAMA,2006
5. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007
Cited by 132 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers;Drug Resistance Updates;2023-03
2. Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib;BJU International;2021-04-19
3. Clinical and Pathological Characteristics of Metastatic Renal Cell Carcinoma Patients Needing a Second-Line Therapy: A Systematic Review;Cancers;2020-12-04
4. Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance;Cancers;2020-10-28
5. Mathematical Modeling Shows That the Response of a Solid Tumor to Antiangiogenic Therapy Depends on the Type of Growth;Mathematics;2020-05-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3